Last reviewed · How we verify
Icosapent (Eicosapentaenoic acid)
Icosapent (generic name: Eicosapentaenoic acid) is a Small molecule drug developed by National Institute on Alcohol Abuse and Alcoholism (NIAAA). It is currently FDA-approved for Breastfeeding (mother), Pregnancy, function. Also known as: Omega-3 fatty acid, Lovaza, EPA, omega-3-acid ethyl esters.
Icosapent is a small molecule omega-3 fatty acid with the chemical name eicosapentaenoic acid (EPA) or icosapentaenoic acid, which is used to treat various conditions including depression, amyotrophic lateral sclerosis, COPD, age-related macular degeneration, and cataract. The exact mechanism of action of icosapent is currently unknown.
At a glance
| Generic name | Eicosapentaenoic acid |
|---|---|
| Also known as | Omega-3 fatty acid, Lovaza, EPA, omega-3-acid ethyl esters, docosahexaenoic acid |
| Sponsor | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| Target | Peroxisome proliferator-activated receptor alpha |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Breastfeeding (mother)
- Pregnancy, function
Common side effects
- Allergic sensitization
Key clinical trials
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting Conditions (NA)
- OMEGA - Dietary Intervention - COPD Trial (NA)
- Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids (NA)
- NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (NA)
- Observing Metabolism of EPA With Consideration of Genetics And Sex (PHASE4)
- NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status (NA)
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Icosapent CI brief — competitive landscape report
- Icosapent updates RSS · CI watch RSS
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) portfolio CI
Frequently asked questions about Icosapent
What is Icosapent?
What is Icosapent used for?
Who makes Icosapent?
What is the generic name of Icosapent?
Is Icosapent also known as anything else?
What development phase is Icosapent in?
What are the side effects of Icosapent?
What does Icosapent target?
Related
- Target: All drugs targeting Peroxisome proliferator-activated receptor alpha
- Manufacturer: National Institute on Alcohol Abuse and Alcoholism (NIAAA) — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Breastfeeding (mother)
- Indication: Drugs for Pregnancy, function
- Also known as: Omega-3 fatty acid, Lovaza, EPA, omega-3-acid ethyl esters, docosahexaenoic acid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing